Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China.

Front Oncol · 2022 · PMC9459234 · PMID 36091105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The median OS was similar, but the HR showed a favorable trend, indicating that this combination strategy could be a potential first-line treatment for non-squamous NSCLC.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.